If losing weight feels harder now than it did a decade ago, you're not imagining it. Your body is going through real hormonal and metabolic changes. Understanding them is the first step toward finding what actually works.

Why is losing weight so hard after 40?

Losing weight after 40 is hard because several body systems change at once: hormones shift, muscle mass drops, insulin sensitivity decreases, and sleep quality declines. These changes aren't about willpower. They're biology.

Hormonal shifts change how your body stores fat

Both women and men go through major hormonal changes in their 40s. For women, dropping estrogen and progesterone levels during perimenopause changes how the body stores and burns fat. Lower estrogen moves fat storage from the hips and thighs to the belly area.

Testosterone also declines in both women and men during this time. Men see a gradual drop — roughly 0.4-1% per year — beginning in the mid-30s. Women experience the drop alongside falling estrogen and progesterone. 

Lower testosterone in either case contributes to reduced muscle mass and a slower metabolism, which makes managing weight harder over time.

Muscle loss slows your metabolism

Sarcopenia is the medical term for age-related muscle loss. Muscle loss begins gradually in the 30s and 40s but accelerates notably after age 50, with the most significant decline after 60.

Adults lose approximately 1% of their muscle mass per year after age 30 — a process that strength training can substantially slow.

Since muscle burns more calories at rest than fat does, this loss means your body needs fewer calories each day. That makes staying at the same weight harder.

Insulin resistance increases with age

As metabolism slows and body composition changes, your cells don't respond to insulin as well. This is called insulin resistance. It makes it harder for your body to control blood sugar. 

It can also lead to more fat storage, especially the deep belly fat around your organs. This type of fat then worsens insulin resistance, creating a tough cycle.

Sleep problems and stress make things worse

Hormonal changes often bring sleep problems, especially for women in perimenopause. Poor sleep can disrupt your body's cortisol rhythm, keeping stress hormone levels elevated when they should be dropping. 

High cortisol promotes fat storage around your midsection and increases appetite. Ongoing stress from work, family, and life changes keeps cortisol high, working against your efforts.

How to start losing weight after 40

You can start losing weight after 40 by focusing on keeping muscle and supporting metabolic health, not just cutting calories. 

Cutting calories too much can slow your metabolism and speed up muscle loss. Adding exercise to a moderate calorie reduction may help protect against this slowdown.

Aim for resistance training 2-3 times per week. Increase your protein intake to support muscle mass. Work on sleep quality and stress management. 

And adjust your expectations: weight management after 40 moves more slowly, but lasting results come from supporting your metabolism, not fighting it.

What actually works for weight loss in your 40s

Effective weight loss in your 40s focuses on building metabolic health, not just cutting calories. Here's how to put that into action with specific strategies you can start today.

Build (or keep) muscle

Strength training becomes critical after 40. It directly fights age-related muscle loss. Building and keeping muscle protects your metabolism and helps your body use insulin better. 

You need more protein as you age to hold onto muscle mass. Your exact needs depend on how active you are, your health, and your goals. 

A registered dietitian can give you personalized guidance. For example,  spreading protein across all your meals (rather than eating most of it at dinner) helps your body preserve muscle better.

Keep blood sugar steady

Blood sugar control matters more as your body becomes less sensitive to insulin. When blood sugar spikes and crashes, it drives hunger, increases fat storage, and causes inflammation.

Eating fewer processed carbohydrates while adding more fiber and healthy fats helps keep blood sugar steady. Complex carbohydrates from vegetables, whole grains, and beans give you lasting energy without the spikes. 

Moving after meals helps too. A short walk after eating helps your muscles absorb sugar from your blood. Research shows that walking has the greatest effect on blood sugar when started as soon as possible after a meal.

Manage sleep, stress, and cortisol

Adults need 7–9 hours of quality sleep each night. Poor sleep increases ghrelin (the hunger hormone) and decreases leptin (the fullness hormone). This makes controlling your appetite much harder. Poor sleep also raises cortisol levels.

High cortisol from ongoing stress promotes belly fat storage and increases cravings for high-calorie foods. Finding ways to manage stress (whether through mindfulness, regular activity, or professional support) can help control cortisol and support your health.

Hormones and weight gain in your 40s

Hormonal changes in your 40s directly influence your metabolism, energy use, and where your body stores fat.

Perimenopause and menopause change your metabolism

Perimenopause usually starts in the 40s. It brings fluctuating and eventually dropping levels of estrogen and progesterone. These hormonal changes affect weight in several ways. 

Lower estrogen makes insulin work less well, which promotes fat storage. It also shifts where fat builds up, moving it toward the belly.  

Progesterone acts like a natural water pill. When levels drop, your body may hold onto more water, which can hide your progress on the scale.

Why belly fat gets more stubborn

Declining estrogen in women and testosterone in men both lead to more belly fat storage. These hormonal changes affect how your body divides nutrients between muscle and fat. The result is more fat around the waist.

High cortisol from chronic stress makes visceral fat build up even faster. This creates the "stress belly" that becomes more common after 40. 

Visceral fat (the deep belly fat around your organs) releases compounds that increase inflammation and insulin resistance throughout your body. This creates a cycle where storing more fat becomes easier over time.

You can’t reliably “burn” fat from just one body part by training that area. So‑called spot reduction has not been supported in controlled studies or meta‑analyses of localized exercise programs.

Instead, exercise helps you lose fat throughout your whole body. Where you lose it first is influenced by genetics, hormones, sex, and overall energy balance, not by which muscles you work the most.

The best approach targets the root causes: manage stress, improve how your body uses insulin, prioritize sleep, and address any hormonal imbalances. Overall, fat loss follows from there.

Hormone therapy considerations

Hormone replacement therapy (HRT) during menopause may help prevent the belly fat gain that often happens after menopause. Studies show HRT can reduce abdominal fat and help keep a healthier body shape, though it doesn't cause weight loss on its own.

HRT works best as part of a full approach that includes nutrition, exercise, and lifestyle changes.

The choice to use HRT needs a personalized assessment by a care team. They can look at your health history, risk factors, and symptoms.

Clinical tools that can help with weight loss

GLP-1 receptor agonists are a class of FDA-approved medications. They were first made for type 2 diabetes but have proven effective for weight management too. 

These include semaglutide (Wegovy for weight management, Ozempic for diabetes) and tirzepatide (Zepbound for weight management, Mounjaro for diabetes).

These medications copy natural hormones that control appetite and blood sugar. They slow how fast food leaves your stomach, helping you feel full longer. They also affect the parts of your brain that control appetite, reducing cravings and overall calorie intake. 

In clinical trials, people using semaglutide (a GLP-1 medication) with lifestyle changes typically lost around 15% of their body weight over 16 months. 

Tirzepatide (a dual GIP/GLP-1 receptor agonist) has shown even greater results, with participants losing over 20% in some studies (at the maximum dosage).

GLP-1 medications usually need ongoing use for lasting benefit. Weight recurrence often happens when treatment stops because the underlying hormonal drive remains. 

This makes these medications appropriate for long-term use in the right candidates, similar to other chronic conditions.

Knowing how much weight you can realistically lose per month helps set good expectations, whether you're using medication or not. Quick fixes like liquid diets rarely give lasting results without addressing underlying metabolic factors.

Disclaimer: GLP-1 medications require a prescription and medical supervision. Talk to your clinicians to determine if these medications are appropriate for your health situation.

When to talk to a provider

Think about seeking medical support if you notice:

• Ongoing fatigue even when you sleep enough
• Unexplained weight changes or inability to lose weight despite consistent healthy habits
• Intense hunger that gets in the way of daily life
• Major changes in body shape or where fat builds up
• Trouble falling or staying asleep
• Mood changes that affect your motivation and eating
• Irregular periods or other signs of hormonal imbalance

If several months of consistent effort (enough protein, regular strength training, good sleep, stress management) haven't led to the results you expected, a care team can help figure out what's getting in the way.

When lifestyle changes aren't enough: Get the medical support you're missing

Building muscle, managing stress, and prioritizing sleep all support weight management after 40. But these strategies are only part of a bigger picture. Research shows that addressing hormonal and metabolic factors, not just behavior, leads to the best results.

When progress stalls, it's not because you're doing anything wrong. Weight regulation is complex. Hormones, metabolism, medications, and medical conditions all play a role in how your body responds to food and activity.

What knownwell offers:

• Physicians who specialize in metabolic health and hormonal factors
• Registered dietitians for medical nutrition therapy and ongoing guidance
• Personalized care plans for the unique challenges of weight management after 40
• FDA-approved medications when medically appropriate
• Compassionate, judgment-free support from experienced clinicians

This kind of team-based care helps you find what works for your body when it comes to losing weight after 40.

Ready to get started?

• Virtual visits: Available from home in all 50 states
• In-person clinics: Boston area, Chicago, Dallas/Fort Worth, and Atlanta
• Insurance accepted: Most major plans offer coverage. See if we accept your insurance.

Connect with knownwell to find the right mix of nutrition, medical support, and lifestyle strategies for your body, so you can feel stronger, more energized, and confident in your health journey.

Frequently asked questions

What's the best way to eat for losing weight after 40?

The best way to eat for losing weight after 40 includes adequate protein (about 1.2-1.6 grams per kilogram of body weight daily during weight management), fiber-rich vegetables, and whole grains.

The exact balance depends on your activity level, metabolic health, and food preferences. A registered dietitian can help you find what works for your body.

Can I get rid of belly fat after menopause?

Yes, you can get rid of belly fat after menopause with patience and a full approach. 

Focus on strategies that improve how your body uses insulin: regular strength training to preserve muscle and support metabolism, enough protein at each meal, consistent sleep (7-9 hours nightly), stress management, and fewer processed carbs.

Do hormones cause weight gain in your 40s?

Yes, hormones contribute to weight gain in your 40s. Declining estrogen, along with changes in progesterone and testosterone, are linked to a slower metabolic rate, loss of lean mass, and a shift toward more abdominal fat.

But weight changes during this time come from a mix of hormonal shifts, lifestyle factors, sleep quality, stress levels, and activity patterns.

What type of exercise is best after 40?

The best type of exercise after 40 is resistance training because it preserves and builds muscle mass, which protects your metabolic rate. 

Aim for 2-3 strength training sessions per week targeting all major muscle groups. Combine this with regular cardio like walking, cycling, or swimming.

Is strength training necessary for weight loss after 40?

Yes, strength training is necessary for weight loss after 40 because it fights the muscle loss that slows metabolism with age. Losing muscle drops your metabolic rate even more, making it harder to hold your weight over time. 

Resistance training keeps muscle mass during weight loss, supports metabolic rate, and improves insulin sensitivity.

Can GLP-1 medications help with weight loss in your 40s?

Yes, FDA-approved GLP-1 medications like semaglutide (Wegovy) and tirzepatide (Zepbound) can support weight management after 40. They work well for this age group because they address some of the hormonal and metabolic changes that make weight management harder. 

They work best as part of care that includes nutrition guidance, physical activity, and lifestyle support.

Should I try intermittent fasting at this age?

Intermittent fasting can work for some people over 40, but it's not right for everyone. Time-restricted eating (limiting food to an 8-12 hour window daily) can support weight management and improve insulin sensitivity in some people.

If you're already dealing with a lot of stress, sleep problems, or irregular eating patterns, a consistent meal schedule may be a better fit. A registered dietitian can help you figure out what works for your body.

What if I've already tried everything and nothing is working?

If you've tried everything and nothing is working, several factors could be getting in the way. These include medical conditions like hypothyroidism, PCOS, insulin resistance, or sleep apnea. 

Some medications cause weight gain as a side effect. A thorough medical evaluation can find which factors are creating roadblocks for you.

Source list

Aggarwal, B., Kodoth, V., Scaccia, S. (2022). Adverse changes in body composition during the menopausal transition and relation to cardiovascular risk: A contemporary review. Women’s Health Report, 3(1), 573-581. doi:10.1089/whr.2021.0119. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC9258798/

American College of Sports Medicine. (2011). Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: Guidance for prescribing exercise. Medicine & Science in Sports & Exercise, 43(7), 1334-1359. doi:10.1249/MSS.0b013e318213fefb. Retrieved from https://journals.lww.com/acsm-msse/fulltext/2011/07000/quantity_and_quality_of_exercise_for_developing.26.aspx

Arrabal, C., Baena, C., Domínguez, R., et al. (2021). A proposed model to test the hypothesis of exercise-induced localized fat reduction (spot reduction), including a systematic review with meta-analysis. Journal of Functional Morphology and Kinesiology, 6(4), 87. doi:10.3390/jfmk6040087. Retrieved from https://www.researchgate.net/publication/355379614_A_proposed_model_to_test_the_hypothesis_of_exercise-induced_localized_fat_reduction_spot_reduction_including_a_systematic_review_with_meta-analysis

Barber, T. M. (2022). Why are women with polycystic ovary syndrome obese? British Medical Bulletin, 143(1), 4-15. doi:10.1093/bmb/ldac007. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC9494255/

Bray, G. A., Heisel, W. E., Afshin, A., et al. (2018). The science of obesity management: An Endocrine Society scientific statement. Endocrine Reviews, 39(2), 79-132. doi:10.1210/er.2017-00253. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC5888222/

Buckinx, F., Aubertin-Leheudre, M. (2022). Sarcopenia in menopausal women: Current perspectives. International Journal of Women’s Health, 14, 805-819. doi:10.2147/IJWH.S340537. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC9235827/

Campos, V., Tappy, L., Bally, L., et al. (2022). Importance of carbohydrate quality: What does it mean and how to measure it? Journal of Nutrition, 152(5), 1200–1206. doi:10.1093/jn/nxac039. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC9071307/

Cava, E., Yeat, N. C., Mittendorfer, B. (2017). Preserving healthy muscle during weight loss. Advances in Nutrition, 8(3), 511–519. doi:10.3945/an.116.014506. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC5421125/

Cheng, H., Zhang, X., Li, Y., et al. (2024). Age-related testosterone decline: Mechanisms and intervention strategies. Reproductive Biology and Endocrinology, 22, 144. doi:10.1186/s12958-024-01316-5. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC11562514/

Chu, J., Zhang, H., Wu, Y., et al. (2025). Efficacy of lifestyle modification combined with GLP-1 receptor agonists on body weight and cardiometabolic biomarkers in individuals with overweight or obesity: A systematic review and meta-analysis. eClinicalMedicine, 78, 103464. doi:10.1016/j.eclinm.2025.103464. Retrieved from https://www.sciencedirect.com/science/article/pii/S2589537025003967

Chait, A., den Hartigh, L. J. (2020). Adipose tissue distribution, inflammation and its metabolic consequences, including diabetes and cardiovascular disease. Frontiers in Cardiovascular Medicine, 7, 22. doi:10.3389/fcvm.2020.00022. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC7052117/

Cifuentes, L., Galbiati, F., Mahmud, H., et al. (2024). Weight regain after total meal replacement very low-calorie diet program with and without anti-obesity medications. Obesity Science & Practice, 10(1), e722. doi:10.1002/osp4.722. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC10804351/

Collins, L., Costello, R. A. (2024). Glucagon-Like Peptide-1 Receptor Agonists. In StatPearls. Treasure Island (FL): StatPearls Publishing. Updated February 29, 2024. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK551568/

Consitt, L. A., Dudley, C., Saxena, G. (2019). Impact of endurance and resistance training on skeletal muscle glucose metabolism in older adults. Nutrients, 11(11), 2636. doi:10.3390/nu11112636. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC6893763/

Corona, G., Rastrelli, G., Morgentaler, A., et al. (2020). Testosterone therapy for prevention and treatment of obesity in men. Androgens: Clinical Research and Therapeutics, 1(1), 32-47. doi:10.1089/andro.2020.0010. Retrieved from https://www.liebertpub.com/doi/10.1089/andro.2020.0010

Delamater, L., Santoro, N. (2018). Management of the perimenopause. Clinical Obstetrics and Gynecology, 61(3), 419-432. doi:10.1097/GRF.0000000000000373. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC6082400/

De Paoli, M., Zakharia, A., Werstuck, G. H. (2021). The role of estrogen in insulin resistance: A review of clinical and preclinical data. American Journal of Pathology, 191(9), 1490-1498. doi:10.1016/j.ajpath.2021.05.011.

Dhokte, S., Czaja, K. (2024). Visceral adipose tissue: The hidden culprit for type 2 diabetes. Nutrients, 16(7), 1015. doi:10.3390/nu16071015. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC11013274/

Engeroff, T., Groneberg, D. A., Wilke, J. (2023). After dinner rest a while, after supper walk a mile? A systematic review with meta-analysis on the acute postprandial glycemic response to exercise before and after meal ingestion in healthy subjects and patients with impaired glucose tolerance. Sports Medicine, 53(4), 849-869. doi:10.1007/s40279-022-01808-7. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC10036272/

Framnes, S. N., Arble, D. M. (2018). The bidirectional relationship between obstructive sleep apnea and metabolic disease. Frontiers in Endocrinology, 9, 440. doi:10.3389/fendo.2018.00440. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC6087747/

Garvey, W. T., Batterham, R. L., Bhatta, M., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: The STEP 5 trial. Nature Medicine, 28(10), 2083-2091. doi:10.1038/s41591-022-02026-4. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC9556320/

Gomes, S., Ramalhete, C., Ferreira, I., Bicho, M., et al. (2023). Sleep patterns, eating behavior and the risk of noncommunicable diseases. Nutrients, 15(11), 2462. doi:10.3390/nu15112462. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC10255419/

Hall, K. D., Kahan, S. (2018). Maintenance of lost weight and long-term management of obesity. Medical Clinics of North America, 102(1), 183-197. doi:10.1016/j.mcna.2017.08.012. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC5764193/

Hamdy, O., Khardori, R. (2024). Insulin resistance. In StatPearls. Treasure Island, FL: StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK507839/

Harris, S., DePalma, J., Barkoukis, H. (2025). Protein and aging: Practicalities and practice. Nutrients, 17(15), 2461. doi:10.3390/nu17152461. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12348035/

Heymsfield, S. B., Thomas, D. M., Bosy-Westphal, A., et al. (2019). The anatomy of resting energy expenditure: Body composition mechanisms. European Journal of Clinical Nutrition, 73(2), 166–171. doi:10.1038/s41430-018-0319-3. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC6410366/

Hirshkowitz, M., Whiton, K., Albert, S. M., et al. (2015). National Sleep Foundation's sleep time duration recommendations: Methodology and results summary. Sleep Health, 1(1), 40-43. doi:10.1016/j.sleh.2014.12.010.

Hunter, G. R., Gower, B. A., Kane, B. L. (2010). Age related shift in visceral fat. International Journal of Body Composition Research, 8(3), 103-108. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC4018766/

Jensen Kolnes, K., Houborg Petersen, M., Lien-Iversen, T.,et al. (2021). Effect of exercise training on fat loss-Energetic perspectives and the role of improved adipose tissue function and body fat distribution. Frontiers in Physiology, 12, 737709. doi:10.3389/fphys.2021.737709. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC8497689/

Kapoor, E., Kling, J. M., Lobo, A. S., et al. (2021). Menopausal hormone therapy in women with medical conditions. Best Practice & Research Clinical Endocrinology & Metabolism, 35(6), 101578. doi:10.1016/j.beem.2021.101578. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC8648973/

Kawai, T., Autieri, M. V., Scalia, R. (2021). Adipose tissue inflammation and metabolic dysfunction in obesity. American Journal of Physiology-Cell Physiology, 320(3), C375-C391. doi:10.1152/ajpcell.00379.2020. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC8294624/

Kravitz, H. M., Kazlauskaite, R., Joffe, H. (2018). Sleep, health, and metabolism in midlife women and menopause: Food for thought. Obstetrics and Gynecology Clinics of North America, 45(4), 679-694. doi:10.1016/j.ogc.2018.07.008. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC6338227/

Larsson, L., Degens, H., Li, M., Salviati, L., et al. (2019). Sarcopenia: Aging-related loss of muscle mass and function. Physiological Reviews, 99(1), 427-511. doi:10.1152/physrev.00061.2017. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC6442923/

Liu, L., Chen, W., Wu, D., et al. (2022). Metabolic efficacy of time-restricted eating in adults: A systematic review and meta-analysis of randomized controlled trials. Journal of Clinical Endocrinology & Metabolism, 107(12), 3428-3441. doi:10.1210/clinem/dgac570.

Lizcano, F., Guzmán, G. (2014). Estrogen deficiency and the origin of obesity during menopause. BioMed Research International, 2014, 757461. doi:10.1155/2014/757461. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC3964739/

Lobo, R. A., Pickar, J. H., Stevenson, J. C., et al (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 29(7), 767–794. doi:10.1097/GME.0000000000002028. Retrieved from https://journals.lww.com/menopausejournal/abstract/2022/07000/the_2022_hormone_therapy_position_statement_of_the.4.aspx

Lovre, D., Lindsey, S. H., Mauvais-Jarvis, F. (2017). Effect of menopausal hormone therapy on components of the metabolic syndrome. Therapeutic Advances in Cardiovascular Disease, 11(1), 33-43. doi:10.1177/1753944716649358. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC5933555/

Młynarska, E., Bojdo, K., Bulicz, A., et al. (2025). Obesity as a multifactorial chronic disease: Molecular mechanisms, systemic impact, and emerging digital interventions. Current Issues in Molecular Biology, 47(10), 787. doi:10.3390/cimb47100787. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12564886/

Most, J., Redman, L. M. (2020). Impact of calorie restriction on energy metabolism in humans. Experimental Gerontology, 133, 110875. doi:10.1016/j.exger.2020.110875. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC9036397/

O’Byrne, N. A., Yuen, F., Butt, W. Z., et al. (2021). Sleep and circadian regulation of cortisol: A short review. Current Opinion in Endocrine and Metabolic Research, 18, 178-186. doi:10.1016/j.coemr.2021.03.011. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC8813037/

Ogawa, S., Yakabe, M., & Akishita, M. (2016). Age-related sarcopenia and its pathophysiological bases. Inflammation and Regeneration, 36, 17. doi:10.1186/s41232-016-0022-5. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC5725797/

Papatriantafyllou, E., Efthymiou, D., Zoumbaneas, E., et al. (2022). Sleep deprivation: Effects on weight loss and weight loss maintenance. Nutrients, 14(8), 1549. doi:10.3390/nu14081549. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC9031614/

Patel, P., Patil, S., Kaur, N. (2025). Estrogen and metabolism: Navigating hormonal transitions from perimenopause to postmenopause. Journal of Mid-life Health, 16(3), 247-256. doi:10.4103/jmh.jmh_75_25. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12431702/

Patil, N., Rehman, A., Anastasopoulou, C., et al. (2024). Hypothyroidism. In StatPearls. Treasure Island, FL: StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK519536/

Rizvi, A. A., Rizzo, M. (2024). Age-related changes in insulin resistance and muscle mass: Clinical implications in obese older adults. Medicina, 60(10), 1648. doi:10.3390/medicina60101648. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC11509678/

Rogerson, O., Wilding, S., Prudenzi, A., et al. (2023). Effectiveness of stress management interventions to change cortisol levels: A systematic review and meta-analysis. Psychoneuroendocrinology, 152, 106415. doi:10.1016/j.psyneuen.2023.106415. Retrieved from https://www.sciencedirect.com/science/article/pii/S0306453023003931

Sallam, M., Snygg, J., El Ghandour, S., et al. (2025). Efficacy and safety of tirzepatide for weight management in non-diabetic obese individuals: A narrative review. Obesities, 5(2), 26. doi:10.3390/obesities5020026. Retrieved from https://www.mdpi.com/2673-4168/5/2/26

Santarpia, L., Contaldo, F., Pasanisi, F. (2017). Dietary protein content for an optimal diet: A clinical view. Journal of Cachexia, Sarcopenia and Muscle, 8(3), 345–348. doi:10.1002/jcsm.12176. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC5476844/

Stachenfeld, N. S. (2014). Hormonal changes during menopause and the impact on fluid regulation. Reproductive Sciences, 21(5), 555–561. doi:10.1177/1933719113518992. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC3984489/

Su, H., Lan, X., Wang, J., et al. (2025). Effects of resistance training and aerobic training on improving the composition of middle-aged adults with obesity in an interventional study. Scientific Reports, 15, 33972. doi:10.1038/s41598-025-11076-w. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12484634/

Troìa, L., Garassino, M., Volpicelli, A. I., et al. (2025). Sleep disturbance and perimenopause: A narrative review. Journal of Clinical Medicine, 14(5), 1479. doi:10.3390/jcm14051479. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC11901009/

U.S. Food and Drug Administration. (2025). Mounjaro (tirzepatide) injection, for subcutaneous use: Prescribing information. U.S. Food and Drug Administration. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215866s031lbl.pdf

U.S. Food and Drug Administration. (2025). Ozempic (semaglutide) injection, for subcutaneous use: Prescribing information. U.S. Food and Drug Administration. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s025lbl.pdf

U.S. Food and Drug Administration. (2025). Wegovy (semaglutide) injection, for subcutaneous use: Prescribing information. U.S. Food and Drug Administration. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf

U.S. Food and Drug Administration. (2025). Zepbound (tirzepatide) injection, for subcutaneous use: Prescribing information. U.S. Food and Drug Administration. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217806Orig1s020lbl.pdf

van der Valk, E. S., Savas, M., van Rossum, E. F. C. (2018). Stress and obesity: Are there more susceptible individuals? Current Obesity Reports, 7(2), 193-203. doi:10.1007/s13679-018-0306-y. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC5958156/

Verhaegen, A. A., Van Gaal, L. F. (2019). Drugs that affect body weight, body fat distribution, and metabolism. In L. J. De Groot, G. Chrousos, K. Dungan, et al. (Eds.), Endotext. South Dartmouth (MA): MDText.com, Inc. Last updated February 11, 2019. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK537590/

Wadden, T. A., Chao, A. M., Moore, M., et al. (2023). The role of lifestyle modification with second-generation anti-obesity medications: Comparisons, questions, and clinical opportunities. Current Obesity Reports, 12(4), 453–473. doi:10.1007/s13679-023-00534-z. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC10748770/

Wang, J.-Y., Wang, Q.-W., Yang, X.-Y., et al. (2023). GLP-1 receptor agonists for the treatment of obesity: Role as a promising approach. Frontiers in Endocrinology, 14, 1112064. doi:10.3389/fendo.2023.1112064. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC9945324/

Wilding, J. P. H., Batterham, R. L., Davies, M., et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553–1564. doi:10.1111/dom.14725. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC9542252/

Williamson, E. (2023). How dietary amino acids and high protein diets influence insulin, glucagon and glucagon-like peptide 1 secretion. Physiological Reports, 11(2), e15577. doi:10.14814/phy2.15577. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC9875820/

Wondmkun, Y. T. (2020). Obesity, insulin resistance, and type 2 diabetes: Associations and therapeutic implications. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 13, 3611–3616. doi:10.2147/DMSO.S275898. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC7553667/

Wyatt, P., Berry, S. E., Finlayson, G., et al. (2021). Postprandial glycaemic dips predict appetite and energy intake in healthy individuals. Nature Metabolism, 3(4), 523–529. doi:10.1038/s42255-021-00383-x. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC7610681/